Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 3.05
EDAP's Cash to Debt is ranked higher than
53% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. EDAP: 3.05 )
Ranked among companies with meaningful Cash to Debt only.
EDAP' s Cash to Debt Range Over the Past 10 Years
Min: 0.37  Med: 9999.00 Max: No Debt
Current: 3.05
Equity to Asset 0.40
EDAP's Equity to Asset is ranked lower than
81% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. EDAP: 0.40 )
Ranked among companies with meaningful Equity to Asset only.
EDAP' s Equity to Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.40 Max: 1
Current: 0.4
0.25
1
F-Score: 4
Z-Score: 2.12
M-Score: -1.90
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -5.39
EDAP's Operating margin (%) is ranked lower than
59% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 1.89 vs. EDAP: -5.39 )
Ranked among companies with meaningful Operating margin (%) only.
EDAP' s Operating margin (%) Range Over the Past 10 Years
Min: -18.31  Med: -12.16 Max: -6.36
Current: -5.39
-18.31
-6.36
Net-margin (%) 9.55
EDAP's Net-margin (%) is ranked higher than
75% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 0.95 vs. EDAP: 9.55 )
Ranked among companies with meaningful Net-margin (%) only.
EDAP' s Net-margin (%) Range Over the Past 10 Years
Min: -53.64  Med: -18.89 Max: 6.93
Current: 9.55
-53.64
6.93
ROE (%) 18.03
EDAP's ROE (%) is ranked higher than
88% of the 286 Companies
in the Global Medical Devices industry.

( Industry Median: 2.05 vs. EDAP: 18.03 )
Ranked among companies with meaningful ROE (%) only.
EDAP' s ROE (%) Range Over the Past 10 Years
Min: -111.74  Med: -26.80 Max: 9.74
Current: 18.03
-111.74
9.74
ROA (%) 12.69
EDAP's ROA (%) is ranked higher than
90% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: -0.07 vs. EDAP: 12.69 )
Ranked among companies with meaningful ROA (%) only.
EDAP' s ROA (%) Range Over the Past 10 Years
Min: -31.62  Med: -13.18 Max: 3.46
Current: 12.69
-31.62
3.46
ROC (Joel Greenblatt) (%) -0.15
EDAP's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 314 Companies
in the Global Medical Devices industry.

( Industry Median: 3.57 vs. EDAP: -0.15 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
EDAP' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -65.88  Med: -36.08 Max: 23.45
Current: -0.15
-65.88
23.45
Revenue Growth (3Y)(%) -14.00
EDAP's Revenue Growth (3Y)(%) is ranked lower than
84% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. EDAP: -14.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
EDAP' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -17.3  Med: -1.40 Max: 11
Current: -14
-17.3
11
EBITDA Growth (3Y)(%) -43.90
EDAP's EBITDA Growth (3Y)(%) is ranked lower than
93% of the 183 Companies
in the Global Medical Devices industry.

( Industry Median: 2.60 vs. EDAP: -43.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
EDAP' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -66.5  Med: -18.50 Max: 157.1
Current: -43.9
-66.5
157.1
EPS Growth (3Y)(%) -33.50
EDAP's EPS Growth (3Y)(%) is ranked lower than
88% of the 187 Companies
in the Global Medical Devices industry.

( Industry Median: 2.90 vs. EDAP: -33.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
EDAP' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -36.3  Med: -16.45 Max: 253.6
Current: -33.5
-36.3
253.6
» EDAP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

EDAP Guru Trades in Q4 2014

Robert Bruce 1,565,494 sh (unchged)
» More
Q1 2015

EDAP Guru Trades in Q1 2015

Robert Bruce 1,565,494 sh (unchged)
» More
Q2 2015

EDAP Guru Trades in Q2 2015

Robert Bruce 1,565,494 sh (unchged)
» More
Q3 2015

EDAP Guru Trades in Q3 2015

Robert Bruce 1,345,494 sh (-14.05%)
» More
» Details

Insider Trades

Latest Guru Trades with EDAP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 27.40
EDAP's P/E(ttm) is ranked lower than
54% of the 260 Companies
in the Global Medical Devices industry.

( Industry Median: 28.39 vs. EDAP: 27.40 )
Ranked among companies with meaningful P/E(ttm) only.
EDAP' s P/E(ttm) Range Over the Past 10 Years
Min: 5.1  Med: 28.50 Max: 50.95
Current: 27.4
5.1
50.95
Forward P/E 34.97
EDAP's Forward P/E is ranked lower than
87% of the 182 Companies
in the Global Medical Devices industry.

( Industry Median: 18.42 vs. EDAP: 34.97 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 30.40
EDAP's PE(NRI) is ranked lower than
56% of the 200 Companies
in the Global Medical Devices industry.

( Industry Median: 27.40 vs. EDAP: 30.40 )
Ranked among companies with meaningful PE(NRI) only.
EDAP' s PE(NRI) Range Over the Past 10 Years
Min: 5.03  Med: 31.15 Max: 50.95
Current: 30.4
5.03
50.95
P/B 5.75
EDAP's P/B is ranked lower than
95% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. EDAP: 5.75 )
Ranked among companies with meaningful P/B only.
EDAP' s P/B Range Over the Past 10 Years
Min: 0.5  Med: 2.64 Max: 18.2
Current: 5.75
0.5
18.2
P/S 2.63
EDAP's P/S is ranked lower than
58% of the 383 Companies
in the Global Medical Devices industry.

( Industry Median: 2.18 vs. EDAP: 2.63 )
Ranked among companies with meaningful P/S only.
EDAP' s P/S Range Over the Past 10 Years
Min: 0.3  Med: 1.39 Max: 5.98
Current: 2.63
0.3
5.98
EV-to-EBIT -4695.94
EDAP's EV-to-EBIT is ranked lower than
99.99% of the 270 Companies
in the Global Medical Devices industry.

( Industry Median: 24.10 vs. EDAP: -4695.94 )
Ranked among companies with meaningful EV-to-EBIT only.
EDAP' s EV-to-EBIT Range Over the Past 10 Years
Min: -8206.3  Med: -10.55 Max: 186.8
Current: -4695.94
-8206.3
186.8
EV-to-EBITDA 51.03
EDAP's EV-to-EBITDA is ranked lower than
99.99% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 16.11 vs. EDAP: 51.03 )
Ranked among companies with meaningful EV-to-EBITDA only.
EDAP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -793.7  Med: -2.60 Max: 753.7
Current: 51.03
-793.7
753.7
Current Ratio 2.04
EDAP's Current Ratio is ranked lower than
63% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.66 vs. EDAP: 2.04 )
Ranked among companies with meaningful Current Ratio only.
EDAP' s Current Ratio Range Over the Past 10 Years
Min: 1.27  Med: 2.34 Max: 3.92
Current: 2.04
1.27
3.92
Quick Ratio 1.61
EDAP's Quick Ratio is ranked lower than
59% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. EDAP: 1.61 )
Ranked among companies with meaningful Quick Ratio only.
EDAP' s Quick Ratio Range Over the Past 10 Years
Min: 1.07  Med: 2.12 Max: 3.51
Current: 1.61
1.07
3.51
Days Inventory 82.90
EDAP's Days Inventory is ranked higher than
76% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 142.23 vs. EDAP: 82.90 )
Ranked among companies with meaningful Days Inventory only.
EDAP' s Days Inventory Range Over the Past 10 Years
Min: 95.66  Med: 107.86 Max: 131.94
Current: 82.9
95.66
131.94
Days Sales Outstanding 128.36
EDAP's Days Sales Outstanding is ranked lower than
81% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 72.25 vs. EDAP: 128.36 )
Ranked among companies with meaningful Days Sales Outstanding only.
EDAP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 110.96  Med: 187.90 Max: 249.93
Current: 128.36
110.96
249.93
Days Payable 110.19
EDAP's Days Payable is ranked higher than
74% of the 256 Companies
in the Global Medical Devices industry.

( Industry Median: 59.85 vs. EDAP: 110.19 )
Ranked among companies with meaningful Days Payable only.
EDAP' s Days Payable Range Over the Past 10 Years
Min: 104.29  Med: 122.21 Max: 171.02
Current: 110.19
104.29
171.02

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 9.59
EDAP's Price/Net Current Asset Value is ranked lower than
66% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 8.50 vs. EDAP: 9.59 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
EDAP' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.29  Med: 3.26 Max: 19.45
Current: 9.59
0.29
19.45
Price/Tangible Book 7.04
EDAP's Price/Tangible Book is ranked lower than
61% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 4.04 vs. EDAP: 7.04 )
Ranked among companies with meaningful Price/Tangible Book only.
EDAP' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.22  Med: 2.41 Max: 16.68
Current: 7.04
0.22
16.68
Price/Median PS Value 1.88
EDAP's Price/Median PS Value is ranked lower than
90% of the 384 Companies
in the Global Medical Devices industry.

( Industry Median: 0.95 vs. EDAP: 1.88 )
Ranked among companies with meaningful Price/Median PS Value only.
EDAP' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.23  Med: 0.64 Max: 4.19
Current: 1.88
0.23
4.19
Price/Graham Number 3.08
EDAP's Price/Graham Number is ranked lower than
59% of the 269 Companies
in the Global Medical Devices industry.

( Industry Median: 2.92 vs. EDAP: 3.08 )
Ranked among companies with meaningful Price/Graham Number only.
EDAP' s Price/Graham Number Range Over the Past 10 Years
Min: 0.08  Med: 0.35 Max: 2.9
Current: 3.08
0.08
2.9

More Statistics

Revenue(Mil) $30
EPS $ 0.09
Beta1.05
Short Percentage of Float5.17%
52-Week Range $2.59 - 6.57
Shares Outstanding(Mil)24.96

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 35 40 45 51
EPS($) -0.32 0.04 0.11 0.21
EPS without NRI($) -0.32 0.04 0.11 0.21

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:EDA.Germany,
Edap TMS SA was incorporated on December 3, 1979 as a Societe Anonyme organized under the laws of the Republic of France for 60 years from the date of incorporation. It is a holding Company and is responsible for providing common services to its subsidiaries, including preparation and consolidation of the financial statements for the group, complying with the requirements of various regulatory agencies and maintaining the listing of its publicly held securities. Its activity is organized in two divisions: HIFU and UDS. Through these two divisions, the Company develops, produces and markets minimally invasive medical devices, mainly for urological diseases. It's HIFU and UDS divisions operate in Europe, the Americas, Asia and the rest of the world. The HIFU division is engaged in the development, manufacturing and marketing of medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. Its HIFU business is quite seasonal and generally linked to lengthy hospital decision and investment processes. In addition to developing, manufacturing and marketing HIFU devices, the HIFU division also generates revenues from leasing equipment, as well as from the sale of disposables, spare parts and maintenance services. Currently, the only commercial product of the Company utilizing HIFU technology is the Ablatherm, an ultrasound guided HIFU device for the treatment of organ-confined prostate cancer. As of December 31, 2013, the HIFU division's patent portfolio contained 36 patents consisting of 16 in the United States, 18 in the European Union and Japan and 2 in Israel and the rest of the world. They belong to 18 groups of patents covering key technologies related to therapeutic ultrasound principles, systems and associated software. The UDS division's main business is producing and marketing devices, known as lithotripters, for the treatment of urinary tract stones by means of ESWL technology. In addition to its manufacturing and selling of lithotripters, the UDS division also generates revenues from the leasing of lithotripters, as well as from the sale of disposables, spare parts and maintenance services. The UDS division offers the Sonolith i-move to small and mid-size hospitals, while the Sonolith i-sys is offered to large hospitals that can afford a fully dedicated and integrated lithotripter. Ablatherm-HIFU device competes with all current treatments for localized tumors, which include surgery, brachytherapy, radiotherapy, cryotherapy and hormonotherapy. The Company and its products are regulated in the United States by the FDA under a number of statutes including the Federal Food, Drug and Cosmetic Act.
» More Articles for EDAP

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
First Prostate Ablation Treatments Performed Using EDAP’s FDA Approved Ablatherm® Robotic HIFU at... Jan 25 2016
EDAP Announces Results of World’s First Focal HIFU Trial Jan 19 2016
EDAP Receives Japanese Approval for Quanta Litho Laser; Secures Exclusive Distribution Rights in... Jan 06 2016
EDAP TMS SA Earnings Analysis: Q3, 2015 By the Numbers Dec 23 2015
EDAP Reports Sale of Ablatherm Robotic HIFU to Sylvester Comprehensive Cancer Center Dec 21 2015
EDAP Receives Russian Regulatory Approval for Focal One(R) HIFU Device Dec 11 2015
EDAP Reports Installation of Ablatherm Robotic HIFU at University of Southern California Dec 09 2015
EDAP Reports Installation of Ablatherm Robotic HIFU at University of Southern California Dec 09 2015
EDAP TMS SA Financials Dec 08 2015
Positive Outcomes From Prostate Cancer Hemiablation Study With EDAP Ablatherm Robotic HIFU Presented... Nov 24 2015
Positive Outcomes From Prostate Cancer Hemiablation Study With EDAP Ablatherm Robotic HIFU Presented... Nov 24 2015
Direction of Market Influences - Research on EVINE Live, hhgregg, Abeona Therapeutics and Edap Tms Nov 23 2015
EDAP Reports Third Quarter 2015 Financial Results and Operational Update Nov 18 2015
EDAP Reports Third Quarter 2015 Financial Results and Operational Update Nov 18 2015
Q3 2015 Edap Tms SA Earnings Release - After Market Close Nov 18 2015
EDAP to Hold Third Quarter 2015 Conference Call on November 19, 2015 Nov 12 2015
EDAP Records First Three U.S. Orders for Ablatherm HIFU Nov 12 2015
EDAP Announces Dismissal of Class Action Lawsuit Nov 11 2015
EDAP TMS SA Due Diligence Report: Upward Trend and Upcoming Catalysts; Investors Anxious Nov 10 2015
EDAP Announces Focal One(R) HIFU Sale to Clinica Santa Maria de Santiago de Chile Nov 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK